Resolvin D1

• UNSPSC Description:

  Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/resolvin-d1.html

• Purity:

  99.60

• Solubility:

  10 mM in DMSO

• Smiles:

  CC/C=C\C[C@@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](C/C=C\CCC(O)=O)O)O)O

• Molecular Weight:

  376.49

• References & Citations:

  [1]Schmid M, et al. Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. J Immunol. 2016 Apr 15;196(8):3429-37.|[2]Gao Y, et al. Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome. J Immunol. 2017 Aug 9. pii: ji1700315.|[3]Benabdoun HA, et al. In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Res Ther. 2019 Mar 12;21(1):72.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Solution, -20°C, 2 years

• Clinical Information:

  No Development Reported

• CAS Number:

  872993-05-0